Research reveals that δ-receptor agonists like KNT-127 alleviate IBS symptoms by modulating gut-brain interactions and ...

The manufacturer of AV-101, an investigational, oral nonopioid, NMDA-targeting therapy to treat neuropathic pain, announced that it has received a U.S. patent for the treatment. AV-101 (4-Cl-KYN) is ...

Irritable bowel syndrome (IBS) is a common digestive disorder with unclear causes, affecting about 10% of the global population. Researchers have now discovered that opioid delta-receptor agonists may ...

In preliminary studies, we discovered that selected typical and atypical antipsychotic drugs interacted with virtually every biogenic amine receptor tested, in confirmation of many prior studies ...

Olfactory receptors are able to detect air-borne odour molecules that enter the nasal cavity and bind to olfactory receptors. The activation of olfactory receptors results in olfactory receptor ...